Skip to content
MedsAcross

Alternatives

Alternatives to Emflaza 22.75 mg/mL oral suspension

4 other presentations of Deflazacort 22.75 mg/mL oral suspension

There are 4 alternatives to this medicine in the catalogue: the same active ingredient (Deflazacort), strength (22.75 mg/mL) and dosage form (oral suspension) from 4 other makers or registers. The table compares packs, storage, lead time, documents and availability.

Side by side

The first row is the medicine you came from.

MedicineManufacturerRegisterPacksStorageLead timeDocumentsAvailability
Emflaza 22.75 mg/mL oral suspensionThis pageOralPTC TherapeuticsUS FDA13 mLStore at 20°C to 25°C (68°F to 77°F). Excursion permitted between 15°C to 30°C (59°F to 86°F). See USP controlled room temperature.On request—Available on request
Deflazacort 22.75 mg/mL oral suspensionOral—US FDA1 bottle, 13 mLStore at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F).On request—Available on request
JAYTHARI Oral Suspension 22.75 mg/mL oral suspensionOralZydus LifesciencesIndiaUS FDA1 bottleStore at 20ºC to 25ºC (68ºF to 77ºF), excursions permitted between 15°C to 30°C (59°F to 86°F).On request—Available on request
Kymbee 22.75 mg/mL oral suspensionOralUpsher-Smith LaboratoriesUS FDA1 bottleStore at 20° to 25°C (68° to 77°F), excursions permitted to 15° to 30°C (59° to 86°F).On request—Available on request
Pyquvi 22.75 mg/mL oral suspensionOralAucta PharmaceuticalsUS FDA13 mLStore at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C to 30°C (59°F to 86°F).On request—Available on request

Alternatives are listed for sourcing. Whether one medicine can replace another is the prescriber's decision, under the rules of the destination country.

For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.

Back to Emflaza 22.75 mg/mL oral suspension

Not sure which maker to choose?

Request a quote for the medicine and we will propose the options that fit your country's import rules and timelines.